| Year |
Citation |
Score |
| 2020 |
Chen KG, Duran GE, Mogul MJ, Wang YC, Ross KL, Jaffrézou JP, Huff LM, Johnson KR, Fojo T, Lacayo NJ, Sikic BI. Genomic stability at the coding regions of the multidrug transporter gene : insights into the development of alternative drug resistance mechanisms in human leukemia cells. Cancer Drug Resistance (Alhambra, Calif.). 3: 959-979. PMID 34541464 DOI: 10.20517/cdr.2020.51 |
0.785 |
|
| 2020 |
Ansell SM, Flinn I, Taylor MH, Sikic BI, Brody J, Nemunaitis J, Feldman A, Hawthorne TR, Rawls T, Keler T, Yellin MJ. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Advances. 4: 1917-1926. PMID 32380537 DOI: 10.1182/Bloodadvances.2019001079 |
0.334 |
|
| 2019 |
Duran GE, Sikic BI. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance. Plos One. 14: e0210879. PMID 30668583 DOI: 10.1371/Journal.Pone.0210879 |
0.36 |
|
| 2018 |
Marcelletti JF, Sikic BI, Cripe LD, Paietta E. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry. Part B, Clinical Cytometry. PMID 30334334 DOI: 10.1002/Cyto.B.21737 |
0.345 |
|
| 2017 |
Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016701508. PMID 28463630 DOI: 10.1200/Jco.2016.70.1508 |
0.339 |
|
| 2017 |
Duran GE, Wang YC, Moisan F, Francisco EB, Sikic BI. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. British Journal of Cancer. PMID 28399108 DOI: 10.1038/Bjc.2017.102 |
0.342 |
|
| 2016 |
Dubey R, Lebensohn A, Bahrami-Nejad Z, Marceau C, Champion M, Gevaert O, Sikic BI, Carette JE, Rohatgi R. Chromatin-remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1. Cancer Research. PMID 27503929 DOI: 10.1158/0008-5472.Can-16-0716 |
0.346 |
|
| 2016 |
Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs. PMID 27424159 DOI: 10.1007/S10637-016-0374-3 |
0.336 |
|
| 2016 |
Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B. Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. Plos One. 11: e0149183. PMID 26886260 DOI: 10.1371/Journal.Pone.0149183 |
0.303 |
|
| 2016 |
Chao MP, McKenna KM, Cha A, Feng D, Liu J, Sikic BI, Majeti R, Weissman IL, Takimoto C, Volkmer J. Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr13 |
0.31 |
|
| 2016 |
Kathawala RJ, Mundy DC, Duran GE, Volkmer J, Kao KS, Wang YC, Bellary A, Weissman IL, Sikic BI. Abstract 4001: The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy Cancer Research. 76: 4001-4001. DOI: 10.1158/1538-7445.Am2016-4001 |
0.301 |
|
| 2016 |
Duran GE, Weitz D, Sémiond D, Gianolio D, Macé S, Sikic BI. Abstract 2140: Cabazitaxel is more active than first generation taxanes inABCB1(+) cell lines due to its higher intracellular accumulation and reduction in ATPase stimulation Cancer Research. 76: 2140-2140. DOI: 10.1158/1538-7445.Am2016-2140 |
0.388 |
|
| 2014 |
Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6295-303. PMID 25324140 DOI: 10.1158/1078-0432.Ccr-14-1373 |
0.3 |
|
| 2014 |
Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Molecular Oncology. 8: 1231-9. PMID 24816187 DOI: 10.1016/J.Molonc.2014.03.016 |
0.331 |
|
| 2014 |
Infante JR, Burris HA, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE, Pilja L, Hawthorne TR, Davis TA, Yellin MJ, Keler T, et al. Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. Journal of Clinical Oncology. 32: 3027-3027. DOI: 10.1200/Jco.2014.32.15_Suppl.3027 |
0.321 |
|
| 2014 |
Ansell SM, Northfelt DW, Flinn I, Burris HA, Dinner SN, Villalobos VM, Sikic BI, Taylor MH, Pilja L, Hawthorne TR, Yellin MJ, Keler T, Davis TA. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. Journal of Clinical Oncology. 32: 3024-3024. DOI: 10.1200/Jco.2014.32.15_Suppl.3024 |
0.316 |
|
| 2014 |
Bachmann F, Burger K, Duran GE, Sikic BI, Lane HA. Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab Cancer Research. 74: 831-831. DOI: 10.1158/1538-7445.Am2014-831 |
0.342 |
|
| 2014 |
Duran GE, Wang YC, Francisco EB, Martinez FJ, Sikic BI. Abstract 763: Resistance to cabazitaxel is associated withABCB1/P-glycoprotein activation, alterations in β-tubulin content and dynamics, reduced BRCA1, and a mesenchymal phenotype in MCF-7 human breast cancer variants Cancer Research. 74: 763-763. DOI: 10.1158/1538-7445.Am2014-763 |
0.362 |
|
| 2013 |
Willis S, Villalobos VM, Young BM, Sikic BI, Leyland-Jones B. Frequently deleted genes in ovarian cancer as indicators of platinum response. Journal of Clinical Oncology. 31: 5583-5583. DOI: 10.1200/Jco.2013.31.15_Suppl.5583 |
0.344 |
|
| 2013 |
Burris H, Ansell S, Neumanitis J, Weiss G, Sikic B, Northfelt D, Pilja L, Davis T, Yellin M, Keler T, Bullock T. A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P127 |
0.331 |
|
| 2012 |
Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1863-9. PMID 22344233 DOI: 10.1158/1078-0432.Ccr-11-1590 |
0.643 |
|
| 2012 |
Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs. 30: 2364-70. PMID 22331549 DOI: 10.1007/S10637-012-9800-3 |
0.368 |
|
| 2012 |
Cabebe EC, Fisher GA, Sikic BI. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Investigational New Drugs. 30: 1082-7. PMID 21404105 DOI: 10.1007/S10637-011-9656-Y |
0.326 |
|
| 2012 |
Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Seetharam S, Snyder LA, Doshi P, Sikic BI. Abstract 817: Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers Cancer Research. 72: 817-817. DOI: 10.1158/1538-7445.Am2012-817 |
0.357 |
|
| 2011 |
Sikic BI, Eckhardt SG, Gallant G, Burris HA, Camidge DR, Colevas AD, Jones SF, Messersmith WA, Wakelee HA, Li H, Kaminker PG, Morris S, Infante JR. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3008. PMID 28022189 DOI: 10.1200/Jco.2011.29.15_Suppl.3008 |
0.311 |
|
| 2011 |
Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Investigational New Drugs. 29: 971-7. PMID 20349264 DOI: 10.1007/S10637-010-9416-4 |
0.336 |
|
| 2011 |
Duran GE, Wang CY, Francisco EB, Wong K, Robinson N, Sikic BI. Abstract LB-351: Comprehensive miRNA profiling of taxane-resistant human breast cancer variants using the SmartChip Real-Time PCR System Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-351 |
0.314 |
|
| 2011 |
Rosen L, LoRusso P, Ma WW, Goldman J, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Gates MR, Jones C, Musib L, Crespigny AD, Chan I, ... Sikic B, et al. Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors Cancer Research. 71: 4716-4716. DOI: 10.1158/1538-7445.Am2011-4716 |
0.334 |
|
| 2011 |
Sultan A, Wang CY, Duran GE, Francisco EB, Berek JS, Sikic BI. Abstract 1401: SYK promotes tumor progression in ovarian cancer cell lines Cancer Research. 71: 1401-1401. DOI: 10.1158/1538-7445.Am2011-1401 |
0.323 |
|
| 2011 |
Musib L, Eppler S, Choo E, Deng A, Miles D, Hsu B, Rosen L, Sikic B, LoRusso P, Ma W, Goldman J, Fisher G, Weise A, Dy G, Chan I, et al. Abstract 1304: Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study Cancer Research. 71: 1304-1304. DOI: 10.1158/1538-7445.Am2011-1304 |
0.324 |
|
| 2011 |
Duran GE, Lane H, Bachmann F, Sikic BI. Abstract C29: Elevated CDKN1A (p21) expression in human cancer cell variants selected for resistance to the novel microtubule depolymerizing agent BAL27862 (active moiety of BAL101553). Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C29 |
0.405 |
|
| 2010 |
Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Molecular Cancer Therapeutics. 9: 2970-81. PMID 21062914 DOI: 10.1158/1535-7163.Mct-10-0780 |
0.308 |
|
| 2010 |
O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the children's oncology group Pediatric Blood and Cancer. 54: 694-702. PMID 20209646 DOI: 10.1002/Pbc.22366 |
0.646 |
|
| 2010 |
Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 376-81. PMID 19633048 DOI: 10.1093/Annonc/Mdp292 |
0.34 |
|
| 2010 |
Sikic BI, Tibshirani R, Lacayo NJ. Reply to D.R. Catchpoole et al Journal of Clinical Oncology. 28: e725. DOI: 10.1200/Jco.2010.32.0283 |
0.604 |
|
| 2010 |
Eckhardt SG, Gallant G, Sikic BI, Camidge DR, Burris HA, Wakelee HA, Messersmith WA, Jones SF, Colevas AD, Infante JR. Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 28: 2580-2580. DOI: 10.1200/Jco.2010.28.15_Suppl.2580 |
0.308 |
|
| 2010 |
Francisco EB, Link JT, Ramsey M, Beck AH, Schwartz E, Rouse R, Fisher GA, Sikic BI. Abstract 4672: Tumor dihydropyrimide dehydrogenase (DPYD) expression is associated with survival in patients with metastatic colorectal cancer treated with gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin (IFOX) Cancer Research. 70: 4672-4672. DOI: 10.1158/1538-7445.Am10-4672 |
0.338 |
|
| 2010 |
Duran GE, Lane H, Bachmann F, Sikic BI. Abstract 4412:In vitroactivity of the novel tubulin active agent BAL27862 inMDR1(+) andMDR1(−) human breast and ovarian cancer variants selected for resistance to taxanes Cancer Research. 70: 4412-4412. DOI: 10.1158/1538-7445.Am10-4412 |
0.35 |
|
| 2010 |
Sultan A, Wang CY, Duran GE, Francisco EB, Berek JS, Sikic BI. Abstract 3496: SYK inhibition results in increased sensitivity of OVCAR-3 cells to paclitaxel Cancer Research. 70: 3496-3496. DOI: 10.1158/1538-7445.Am10-3496 |
0.361 |
|
| 2010 |
Wang CY, Duran GE, Francisco EB, Juric D, Witten D, Tibshrani R, Sikic BI. Abstract 1526: Epithelial mesenchymal transition (EMT) is associated with non-transporter resistance to taxanes in human ovarian cancer cell Cancer Research. 70: 1526-1526. DOI: 10.1158/1538-7445.Am10-1526 |
0.375 |
|
| 2009 |
Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, et al. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. Jama. 302: 276-89. PMID 19602687 DOI: 10.1001/Jama.2009.1022 |
0.325 |
|
| 2009 |
Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leukemia Research. 33: 1055-61. PMID 19108889 DOI: 10.1016/J.Leukres.2008.09.015 |
0.355 |
|
| 2009 |
Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leukemia Research. 33: 769-74. PMID 18976810 DOI: 10.1016/J.Leukres.2008.09.020 |
0.315 |
|
| 2008 |
Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7074-9. PMID 18981005 DOI: 10.1158/1078-0432.Ccr-08-1014 |
0.321 |
|
| 2008 |
Sikic BI, Tibshirani R, Lacayo NJ. Genomics of childhood leukemias: the virtue of complexity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4367-8. PMID 18802145 DOI: 10.1200/Jco.2008.16.4285 |
0.619 |
|
| 2008 |
Wakelee HA, Fehling JM, Molina JR, Lensing JL, Funke RP, Miles D, Sikic BI. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM) Journal of Clinical Oncology. 26: 3528-3528. DOI: 10.1200/Jco.2008.26.15_Suppl.3528 |
0.306 |
|
| 2007 |
Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1341-9. PMID 17312329 DOI: 10.1200/JCO.2006.09.3534 |
0.604 |
|
| 2007 |
Wakelee HA, Molina JR, Fehling JM, Lensing JL, Sikic BI. A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies Journal of Clinical Oncology. 25: 14044-14044. DOI: 10.1200/Jco.2007.25.18_Suppl.14044 |
0.307 |
|
| 2007 |
Sikic BI, Wakelee HA, von Mehren M, Lewis N, Calvert AH, Plummer ER, Fox NL, Howard T, Jones SF, Burris HA. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI Journal of Clinical Oncology. 25: 14006-14006. DOI: 10.1200/Jco.2007.25.18_Suppl.14006 |
0.335 |
|
| 2007 |
Lancet JE, Gotlib J, Wetzler M, Luger S, Cripe LD, Tallman MS, Gojo I, Mulford D, Baer MR, List AF, Multani PS, Sikic BI. Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML). Blood. 110: 299-299. DOI: 10.1182/Blood.V110.11.299.299 |
0.335 |
|
| 2006 |
Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3231-2. PMID 16740740 DOI: 10.1158/1078-0432.Ccr-06-0655 |
0.326 |
|
| 2006 |
Cho CD, Fisher GA, Halsey J, Sikic BI. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Investigational New Drugs. 24: 117-23. PMID 16683204 DOI: 10.1007/S10637-006-2032-7 |
0.311 |
|
| 2006 |
DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 20: 426-32. PMID 16424866 DOI: 10.1038/Sj.Leu.2404102 |
0.628 |
|
| 2006 |
Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes, Chromosomes & Cancer. 45: 365-74. PMID 16382445 DOI: 10.1002/Gcc.20300 |
0.364 |
|
| 2006 |
Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 274-87. PMID 16365179 DOI: 10.1200/Jco.2005.02.9405 |
0.343 |
|
| 2006 |
Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 107: 1315-24. PMID 16254147 DOI: 10.1182/Blood-2004-08-3218 |
0.617 |
|
| 2006 |
Kuo T, Fitzgerald A, Kaiser H, Sikic BI, Fisher GA. A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer Journal of Clinical Oncology. 24: 4122-4122. DOI: 10.1200/Jco.2006.24.18_Suppl.4122 |
0.331 |
|
| 2006 |
Wakelee HA, Adjei AA, Halsey J, Lensing JL, Dugay JD, Hanson LJ, Reid JM, Piens JR, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM) Journal of Clinical Oncology. 24: 3044-3044. DOI: 10.1200/Jco.2006.24.18_Suppl.3044 |
0.33 |
|
| 2006 |
Patnaik A, Wakelee H, Mita M, Fitzgerald A, Hill M, Fox N, Howard T, Ullrich S, Tolcher A, Sikic B. HGS-ETR2—A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors Journal of Clinical Oncology. 24: 3012-3012. DOI: 10.1200/Jco.2006.24.18_Suppl.3012 |
0.341 |
|
| 2006 |
Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas Journal of Clinical Oncology. 24: 1508-1508. DOI: 10.1200/Jco.2006.24.18_Suppl.1508 |
0.354 |
|
| 2006 |
Lancet J, Baer MR, Cripe LD, List AF, Marcelletti JF, Multani PS, Sikic BI. Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML). Blood. 108: 422-422. DOI: 10.1182/Blood.V108.11.422.422 |
0.324 |
|
| 2006 |
Lacayo NJ, O’Brien M, Jain S, Meshinchi S, Yu R, Juric D, Chang MN, Tibshirani R, Ravindranath Y, Weinstein HJ, Sikic BI, Van Houten Dahl G. Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. Blood. 108: 1915-1915. DOI: 10.1182/Blood.V108.11.1915.1915 |
0.615 |
|
| 2005 |
Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proceedings of the National Academy of Sciences of the United States of America. 102: 17763-8. PMID 16306258 DOI: 10.1073/Pnas.0509082102 |
0.331 |
|
| 2005 |
Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Research. 65: 9388-97. PMID 16230402 DOI: 10.1158/0008-5472.Can-04-4133 |
0.631 |
|
| 2005 |
Wakelee HA, Sikic BI. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. Clinical Lung Cancer. 7: S6-12. PMID 16159420 DOI: 10.3816/Clc.2005.S.002 |
0.347 |
|
| 2005 |
Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Investigational New Drugs. 23: 467-77. PMID 16133798 DOI: 10.1007/S10637-005-2906-0 |
0.35 |
|
| 2005 |
Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 1968-73. PMID 16126736 DOI: 10.1093/Annonc/Mdi396 |
0.323 |
|
| 2005 |
Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5613-9. PMID 16110021 DOI: 10.1200/Jco.2005.08.359 |
0.32 |
|
| 2005 |
Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Investigational New Drugs. 23: 311-5. PMID 16012790 DOI: 10.1007/S10637-005-1439-X |
0.372 |
|
| 2005 |
Wakelee H, Adjei AA, Keer H, Halsey J, Hanson L, Reid J, Hutchison S, Piens J, Lacy S, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies Journal of Clinical Oncology. 23: 3142-3142. DOI: 10.1200/Jco.2005.23.16_Suppl.3142 |
0.347 |
|
| 2005 |
Kuo DJ, Lacayo NJ, Hoang D, Juric D, Raimondi SC, Chen D, Chang MN, Ravindranath Y, Weinstein HJ, Sikic BI, Dahl GVH. Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421. Blood. 106: 2771-2771. DOI: 10.1182/Blood.V106.11.2771.2771 |
0.598 |
|
| 2005 |
Lacayo N, Meshinchi S, Raimondi S, Saraiya C, O’Brien M, Yu R, Juric D, Chang M, Willman C, Tibshirani R, Ravindranath Y, Sikic B, Weinstein H, Dahl GVH. Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421. Blood. 106: 2372-2372. DOI: 10.1182/Blood.V106.11.2372.2372 |
0.617 |
|
| 2004 |
Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bulletin Du Cancer. 91: E81-112. PMID 15568225 |
0.69 |
|
| 2004 |
Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, ... Sikic BI, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 104: 2646-54. PMID 15251987 DOI: 10.1182/Blood-2003-12-4449 |
0.616 |
|
| 2004 |
Bredel M, Bredel C, Sikic BI. Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? The Lancet. Oncology. 5: 89-100. PMID 14761812 DOI: 10.1016/S1470-2045(04)01382-8 |
0.302 |
|
| 2004 |
Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer. 100: 321-6. PMID 14716767 DOI: 10.1002/Cncr.11909 |
0.348 |
|
| 2004 |
Lacayo NJ, Meshinchi S, Raimondi SC, Kuo DJ, Yu R, Chang MN, Willman CL, Tibshirani R, Ravindranath Y, Sikic BI, Weinstein H, Dahl GV. FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421. Blood. 104: 570-570. DOI: 10.1182/Blood.V104.11.570.570 |
0.61 |
|
| 2004 |
Kuo DJ, Lacayo NJ, Buck S, Yu R, Saraiya C, Douglas L, Weinstein H, Chang M, Willman CL, Tibshirani R, Dahl GV, Sikic B, Ravindranath Y. Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421. Blood. 104: 1130-1130. DOI: 10.1182/Blood.V104.11.1130.1130 |
0.648 |
|
| 2004 |
DiMartino JF, Lacayo NJ, Varadi M, Ravindranath Y, Yu R, Sikic B, Raimondi SC, Dahl GV. Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines. Blood. 104: 1106-1106. DOI: 10.1182/Blood.V104.11.1106.1106 |
0.629 |
|
| 2003 |
Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, Stockdale FE. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Breast Cancer Research and Treatment. 82: 61-9. PMID 14672404 DOI: 10.1023/B:Brea.0000003920.27391.Ac |
0.322 |
|
| 2003 |
Lacayo NJ, Duran GE, Sikic BI. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. Journal of Experimental Therapeutics & Oncology. 3: 127-35. PMID 14641819 DOI: 10.1046/J.1359-4117.2003.01088.X |
0.65 |
|
| 2002 |
Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes, Chromosomes & Cancer. 34: 372-83. PMID 12112526 DOI: 10.1002/Gcc.10067 |
0.646 |
|
| 2002 |
Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 16: 920-7. PMID 11986955 DOI: 10.1038/Sj.Leu.2402455 |
0.629 |
|
| 2000 |
Chen GK, Durán GE, Mangili A, Beketic-Oreskovic L, Sikic BI. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. British Journal of Cancer. 83: 892-8. PMID 10970691 DOI: 10.1054/Bjoc.2000.1371 |
0.345 |
|
| 2000 |
Yuen AR, Sikic BI. Clinical studies of antisense therapy in cancer. Frontiers in Bioscience : a Journal and Virtual Library. 5: D588-93. PMID 10833467 DOI: 10.2741/Yuen |
0.31 |
|
| 2000 |
Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1867-75. PMID 10784627 DOI: 10.1200/Jco.2000.18.9.1867 |
0.636 |
|
| 2000 |
Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemotherapy and Pharmacology. 45: 305-11. PMID 10755319 DOI: 10.1007/S002800050045 |
0.344 |
|
| 2000 |
Chen GK, Lacayo NJ, Durán GE, Cohen D, Sikic BI. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335). Molecular Pharmacology. 57: 769-77. PMID 10727524 DOI: 10.1124/Mol.57.4.769 |
0.625 |
|
| 1999 |
Sikic BI. New approaches in cancer treatment. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 10: 149-53. PMID 10676567 DOI: 10.1093/Annonc/10.Suppl_6.S149 |
0.331 |
|
| 1999 |
Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, ... Sikic B, et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC) Advances in Experimental Medicine and Biology. 457: 47-56. PMID 10500779 DOI: 10.1007/978-1-4615-4811-9_6 |
0.354 |
|
| 1999 |
Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1061-70. PMID 10071301 DOI: 10.1200/Jco.1999.17.3.1061 |
0.505 |
|
| 1999 |
Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 85: 358-67. PMID 10023703 DOI: 10.1002/(Sici)1097-0142(19990115)85:2<358::Aid-Cncr13>3.0.Co;2-0 |
0.392 |
|
| 1999 |
Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 93: 787-95. PMID 9920827 DOI: 10.1182/Blood.V93.3.787.403K30_787_795 |
0.403 |
|
| 1998 |
Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association. 19: 203-9. PMID 9803961 DOI: 10.1097/00042560-199811010-00001 |
0.32 |
|
| 1998 |
Cufer T, Vrhovec I, Pfeifer M, Skrk J, Borstnar S, Sikic BI. Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemotherapy and Pharmacology. 41: 517-21. PMID 9554598 DOI: 10.1007/S002800050776 |
0.313 |
|
| 1998 |
Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S, Kim AE, Dintaman JM, Waddell DS, Silverman JA, Duran G, Man M, Sikic B, et al. HIV-1 protease inhibitors and the MDR1 multidrug transporter Journal of Clinical Investigation. 101: 287-288. PMID 9435298 DOI: 10.1172/JCI2575 |
0.352 |
|
| 1997 |
Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemotherapy and Pharmacology. 40: S13-9. PMID 9272128 DOI: 10.1007/S002800051055 |
0.411 |
|
| 1997 |
Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, Sikic BI. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. The Journal of Biological Chemistry. 272: 5974-82. PMID 9038218 DOI: 10.1074/Jbc.272.9.5974 |
0.703 |
|
| 1997 |
Kühl JS, Krajewski S, Durán GE, Reed JC, Sikic BI. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. British Journal of Cancer. 75: 268-74. PMID 9010037 DOI: 10.1038/Bjc.1997.44 |
0.375 |
|
| 1996 |
Luckie DB, Krouse ME, Law TC, Sikic BI, Wine JJ. Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. The American Journal of Physiology. 270: C1029-36. PMID 8928730 DOI: 10.1152/Ajpcell.1996.270.4.C1029 |
0.314 |
|
| 1996 |
Dumontet C, Durán GE, Steger KA, Murphy GL, Sussman HH, Sikic BI. Differential expression of tubulin isotypes during the cell cycle. Cell Motility and the Cytoskeleton. 35: 49-58. PMID 8874965 DOI: 10.1002/(Sici)1097-0169(1996)35:1<49::Aid-Cm4>3.0.Co;2-D |
0.482 |
|
| 1996 |
Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. European Journal of Cancer (Oxford, England : 1990). 32: 1082-8. PMID 8763350 DOI: 10.1016/0959-8049(96)00111-6 |
0.37 |
|
| 1996 |
Duran GE, Lau DH, Lewis AD, Kühl JS, Bämmler TK, Sikic BI. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemotherapy and Pharmacology. 38: 210-6. PMID 8646794 DOI: 10.1007/S002800050473 |
0.301 |
|
| 1996 |
Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Research. 56: 1091-7. PMID 8640766 |
0.445 |
|
| 1995 |
Jaffrézou JP, Dumontet C, Derry WB, Durán G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncology Research. 7: 517-27. PMID 8866664 |
0.466 |
|
| 1995 |
Fisher GA, Lum BL, Sikic BI. The reversal of multidrug resistance. Cancer Treatment and Research. 78: 45-70. PMID 8595147 DOI: 10.1007/978-1-4615-2007-8_3 |
0.364 |
|
| 1995 |
Jaffrézou JP, Chen G, Durán GE, Muller C, Bordier C, Laurent G, Sikic BI, Levade T. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochimica Et Biophysica Acta. 1266: 1-8. PMID 7718613 DOI: 10.1016/0167-4889(94)00219-5 |
0.376 |
|
| 1995 |
Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematology/Oncology Clinics of North America. 9: 363-82. PMID 7642468 DOI: 10.1016/S0889-8588(18)30099-6 |
0.362 |
|
| 1995 |
Cufer T, Vrhovec I, Skrk J, Pfeifer M, Pajk B, Zakotnik B, Filipic B, Rode B, Sikic BI. Cyclosporine A increases serum cortisol levels in rabbits. Anti-Cancer Drugs. 6: 615-8. PMID 7579569 DOI: 10.1097/00001813-199508000-00018 |
0.317 |
|
| 1995 |
Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Journal of the National Cancer Institute. 87: 1593-602. PMID 7563202 DOI: 10.1093/Jnci/87.21.1593 |
0.548 |
|
| 1994 |
Lau D, Duran G, Sikic B. Analysis of intracellular retention of morpholinyl anthracyclines in multidrug-resistant cancer-cells by interactive laser cytometry. International Journal of Oncology. 5: 1273-7. PMID 21559709 DOI: 10.3892/Ijo.5.6.1273 |
0.34 |
|
| 1994 |
Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 835-42. PMID 8151326 DOI: 10.1200/Jco.1994.12.4.835 |
0.355 |
|
| 1994 |
Jaffrézou JP, Chen G, Durán GE, Kühl JS, Sikic BI. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. Journal of the National Cancer Institute. 86: 1152-8. PMID 8028036 DOI: 10.1093/Jnci/86.15.1152 |
0.346 |
|
| 1994 |
Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. British Journal of Cancer. 70: 79-84. PMID 8018545 DOI: 10.1038/Bjc.1994.253 |
0.321 |
|
| 1994 |
Yuen AR, Sikic BI. Multidrug resistance in lymphomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 2453-9. PMID 7964963 DOI: 10.1200/Jco.1994.12.11.2453 |
0.306 |
|
| 1994 |
Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J. Clinical reversal of multidrug resistance. Cancer Treatment and Research. 73: 149-65. PMID 7710904 DOI: 10.1007/978-1-4615-2632-2_8 |
0.349 |
|
| 1994 |
Jaffrézou JP, Sikic BI, Laurent G. Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood. 83: 482-9. PMID 7506953 |
0.598 |
|
| 1993 |
Kühl JS, Durán GE, Chao NJ, Sikic BI. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemotherapy and Pharmacology. 33: 10-6. PMID 8269583 DOI: 10.1007/Bf00686016 |
0.358 |
|
| 1993 |
Leyland-Jones B, Dalton W, Fisher GA, Sikic BI. Reversal of multidrug resistance to cancer chemotherapy. Cancer. 72: 3484-8. PMID 8242580 DOI: 10.1002/1097-0142(19931201)72:11+<3484::Aid-Cncr2820721615>3.0.Co;2-L |
0.338 |
|
| 1993 |
Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: Implications of the multidrug resistance gene Pharmacotherapy. 13: 88-109. PMID 8097038 DOI: 10.1002/J.1875-9114.1993.Tb02695.X |
0.419 |
|
| 1993 |
Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 72: 3502-14. PMID 7902206 DOI: 10.1002/1097-0142(19931201)72:11+<3502::Aid-Cncr2820721618>3.0.Co;2-N |
0.383 |
|
| 1992 |
Lewis AD, Durán GE, Lau DH, Sikic BI. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. International Journal of Radiation Oncology, Biology, Physics. 22: 821-4. PMID 1544857 DOI: 10.1016/0360-3016(92)90532-M |
0.35 |
|
| 1992 |
Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 1635-42. PMID 1403041 DOI: 10.1200/Jco.1992.10.10.1635 |
0.364 |
|
| 1992 |
Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 1624-34. PMID 1403040 DOI: 10.1200/Jco.1992.10.10.1624 |
0.353 |
|
| 1991 |
Sikic BI. Anticancer drug discovery Journal of the National Cancer Institute. 83: 738-740. PMID 2041045 DOI: 10.1093/Jnci/83.11.738 |
0.313 |
|
| 1991 |
Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity Blood. 78: 586-592. PMID 1859877 DOI: 10.1182/Blood.V78.3.586.Bloodjournal783586 |
0.373 |
|
| 1991 |
Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity Cancer. 67: 1518-1524. PMID 1848154 DOI: 10.1002/1097-0142(19910315)67:6<1518::Aid-Cncr2820670610>3.0.Co;2-3 |
0.32 |
|
| 1991 |
Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI, Blume KG, Chao NJ. A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy Blood. 77: 2079-2084. PMID 1673356 DOI: 10.1182/Blood.V77.9.2079.2079 |
0.317 |
|
| 1991 |
Carlson RW, Sikic BI, Gandara DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM, Lamborn KR, Phillips TL. Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer Cancer. 68: 948-958. PMID 1655219 DOI: 10.1002/1097-0142(19910901)68:5<948::Aid-Cncr2820680507>3.0.Co;2-1 |
0.3 |
|
| 1990 |
Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF. Modification of cisplatin toxicity with diethyldithiocarbamate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1585-90. PMID 2167955 DOI: 10.1200/Jco.1990.8.9.1585 |
0.327 |
|
| 1990 |
John M, Flam M, Sikic B, Rotman M, Cooper J, Malec M, Hannigan J, Phillips T. Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: A phase I–II prospective intergroup NCOG-RTOG study Gynecologic Oncology. 37: 1-5. PMID 2108909 DOI: 10.1016/0090-8258(90)90296-W |
0.317 |
|
| 1989 |
Lau DHM, Lewis AD, Sikic BI. Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes Journal of the National Cancer Institute. 81: 1034-1038. PMID 2733045 DOI: 10.1093/Jnci/81.13.1034 |
0.304 |
|
| 1988 |
Schray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GD, Sikic BI. Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 6: 1433-9. PMID 3418375 DOI: 10.1200/Jco.1988.6.9.1433 |
0.305 |
|
| 1988 |
Beckman RA, McFall PJ, Sikic BI, Smith SD. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: Comparative in vitro potency against leukemia and bone marrow cells Journal of the National Cancer Institute. 80: 361-365. PMID 3357201 DOI: 10.1093/Jnci/80.5.361 |
0.355 |
|
| 1988 |
Scudder SA, Brown JM, Sikic BI. Dna cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells Journal of the National Cancer Institute. 80: 1294-1298. PMID 3172256 DOI: 10.1093/Jnci/80.16.1294 |
0.327 |
|
| 1986 |
Schray MF, Martinez A, Howes AE, Ballon SC, Podratz KC, Sikic BI, Malkasian GD. Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecologic Oncology. 24: 68-80. PMID 3699578 DOI: 10.1016/0090-8258(86)90009-0 |
0.329 |
|
| 1986 |
DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group Cancer Chemotherapy and Pharmacology. 18: 235-238. PMID 3542268 DOI: 10.1007/Bf00273393 |
0.317 |
|
| 1985 |
Sikic BI, Ehsan MN, Harker WG, Friend NF, Brown BW, Newman RA, Hacker MP, Acton EM. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog Science. 228: 1544-1546. PMID 4012308 DOI: 10.1126/Science.4012308 |
0.347 |
|
| 1984 |
Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK, Reynolds R, Bohnen R, Gandara D, Yu J. Chemotherapy of small-cell carcinoma of lung: A randomized comparison of alternating and sequential combination chemotherapy programs Journal of Clinical Oncology. 2: 1192-1199. PMID 6092554 DOI: 10.1200/Jco.1984.2.11.1192 |
0.303 |
|
| 1983 |
Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy Annals of Internal Medicine. 99: 823-833. PMID 6197002 DOI: 10.7326/0003-4819-99-6-823 |
0.342 |
|
| 1981 |
MacKintosh FR, Evans TL, Sikic BI. Methodologic problems in clonogenic assays of spontaneous human tumors Cancer Chemotherapy and Pharmacology. 6: 205-210. PMID 7032738 DOI: 10.1007/Bf00256972 |
0.301 |
|
| 1980 |
Siddik ZH, Drew R, Litterst CL, Mimnaugh EG, Sikic BI, Gram TE. Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A-deficient rats Pharmacology. 21: 383-390. PMID 7220590 DOI: 10.1159/000137457 |
0.765 |
|
| 1980 |
Sikic BI, Siddik ZH, Gram TE. Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A Cancer Treatment Reports. 64: 659-667. PMID 6159079 |
0.778 |
|
| 1979 |
Drew R, Sikic BI, Mimnaugh EG, Litterst CL, Gram TE. The distribution of 14C-imipramine in mice bearing lewis lung carcinoma Life Sciences. 25: 1813-1820. PMID 529988 DOI: 10.1016/0024-3205(79)90428-4 |
0.766 |
|
| 1979 |
Mimnaugh EG, Siddik ZH, Drew R, Sikic BI, Gram TE. The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice Toxicology and Applied Pharmacology. 49: 119-126. PMID 473197 DOI: 10.1016/0041-008X(79)90284-9 |
0.76 |
|
| 1979 |
Siddik ZH, Sikic BI, Drew R, Mimnaugh EG, Litterst CL, Gram TE. Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism Biochemical Pharmacology. 28: 683-685. PMID 444254 DOI: 10.1016/0006-2952(79)90156-4 |
0.766 |
|
| 1978 |
Litterst CL, Sikic BI, Mimnaugh EG, Guarino AM, Gram TE. In vitro drug metabolism in male and female athymic, nude mice Life Sciences. 22: 1723-1730. PMID 672423 DOI: 10.1016/0024-3205(78)90624-0 |
0.757 |
|
| 1978 |
Mimnaugh EG, Waring RW, Sikic BI, Magin RL, Drew R, Litterst CL, Gram TE, Guarino AM. Effect of whole-body hyperthermia on the disposition and metabolism of adriamycin in rabbits Cancer Research. 38: 1420-1425. PMID 639069 |
0.747 |
|
| 1978 |
Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice Cancer Treatment Reports. 62: 2011-2017. PMID 87269 |
0.78 |
|
| 1978 |
Sikic BI, Young DM, Mimnaugh EG, Gram TE. Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology Cancer Research. 38: 787-792. PMID 75060 |
0.774 |
|
| 1977 |
Sikic BI, Mimnaugh EG, Gram TE. Effects of dietary ascorbic acid supplementation on hepatic drug-metabolizing enzymes in the guinea pig Biochemical Pharmacology. 26: 2037-2041. PMID 411495 DOI: 10.1016/0006-2952(77)90013-2 |
0.763 |
|
| 1977 |
Sikic BI, Mimnaugh EG, Litterst CL, Gram TE. The effects of ascorbic acid deficiency and repletion on pulmonary, renal, and hepatic drug metabolism in the guinea pig Archives of Biochemistry and Biophysics. 179: 663-671. PMID 403863 DOI: 10.1016/0003-9861(77)90155-2 |
0.773 |
|
| Show low-probability matches. |